The Evolution of Target Hemoglobin Levels in Anemia of Chronic Kidney Disease
Publication date: July 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 4Author(s): Jonathan Bazeley, Jay B. WishSince the introduction of erythropoiesis-stimulating agents (ESAs) into clinical practice in 1989, considerable effort has been put forth toward identifying the optimal treatment strategy for managing anemia of CKD. After initial treatment of only the most severely anemic patients, therapy was subsequently expanded to include most patients on dialysis and many nondialysis CKD patients. Many nephrology societies and regulatory agencies have sought to identify the most appropriate hemoglobin levels...
Source: Advances in Chronic Kidney Disease - August 31, 2019 Category: Urology & Nephrology Source Type: research
Low Quality of International Classification of Diseases, 10th Revision, Procedural Coding System Data Undermines the Validity of the Standardized Transfusion Ratio: Time to Chart a New Course?
Publication date: July 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 4Author(s): Eric D. Weinhandl, Kristine M. Kubisiak, James B. WetmoreThe validity of the standardized transfusion ratio, a quality measure for dialysis facilities, may have been affected by the transition from International Classification of Diseases, Ninth Revision (ICD-9) to International Classification of Diseases, Tenth Revision (ICD-10) procedure coding in October 2015. We analyzed Medicare Part A claims for inpatient care among dialysis patients in 2014-2017 and investigated billing patterns for blood transfusion during the last y...
Source: Advances in Chronic Kidney Disease - August 31, 2019 Category: Urology & Nephrology Source Type: research
The Impact of Anemia Treatment on Health-Related Quality of Life in Patients With Chronic Kidney Disease in the Contemporary Era
Publication date: July 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 4Author(s): Fredric O. Finkelstein, Susan H. FinkelsteinThe treatment of anemia with erythropoietic-stimulating agents is now part of the routine care of patients with CKD with guidelines for anemia management carefully outlined by Kidney Disease Improving Global Outcomes. The treatment of anemia impacts the health-related quality of life of CKD patients, primarily affecting the domains of energy/vitality and physical functioning. Improvements in these domains occur, in general, most noticeably when hemoglobin levels are raised from bel...
Source: Advances in Chronic Kidney Disease - August 31, 2019 Category: Urology & Nephrology Source Type: research
Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience
Publication date: July 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 4Author(s): Neil S. Sanghani, Volker H. HaaseProlyl hydroxylase domain oxygen sensors are dioxygenases that regulate the activity of hypoxia-inducible factor (HIF), which controls renal and hepatic erythropoietin production and coordinates erythropoiesis with iron metabolism. Small molecule inhibitors of prolyl hydroxylase domain dioxygenases (HIF-PHI [prolyl hydroxylase inhibitor]) stimulate the production of endogenous erythropoietin and improve iron metabolism resulting in efficacious anemia management in patients with CKD. Three ora...
Source: Advances in Chronic Kidney Disease - August 31, 2019 Category: Urology & Nephrology Source Type: research
Biosimilar Erythropoiesis-Stimulating Agents in Chronic Kidney Disease
Publication date: July 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 4Author(s): Hitesh H. Shah, Steven FishbaneAnemia is a well-known complication of advanced CKD and treatment with erythropoietin analogues (epoetin) remains a key component of management. Although biologic agents, including epoetin, play an extremely important role in the treatment of various medical conditions, their cost can be prohibitive. As a result, several biosimilar agents have now been approved by the U.S. Food and Drug Administration. Biosimilar epoetin has been used in Europe since 2007. In this article, we will review biosim...
Source: Advances in Chronic Kidney Disease - August 31, 2019 Category: Urology & Nephrology Source Type: research
Novel Oral Iron Therapies for Iron Deficiency Anemia in Chronic Kidney Disease
This article covers current treatment guidelines for patients with anemia and CKD and clinical trial data for iron-repletion agents currently in use, as well as for novel oral iron therapies in development. Ferric citrate, a novel oral iron-repletion agent approved for patients with non-dialysis-dependent CKD and IDA, demonstrated improvements in hemoglobin levels and iron parameters, with good tolerability in patients with non-dialysis-dependent CKD. When used as a phosphate binder, ferric citrate also improves hemoglobin and iron parameters in dialysis-dependent CKD, but additional trials are needed to evaluate its effic...
Source: Advances in Chronic Kidney Disease - August 31, 2019 Category: Urology & Nephrology Source Type: research
Long-Term Risks of Intravenous Iron in End-Stage Renal Disease Patients
Publication date: July 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 4Author(s): Abhijit V. Kshirsagar, Xiaojuan LiPatients with end-stage renal disease on dialysis commonly receive intravenous iron to treat anemia along with erythropoiesis-stimulating agents. While studies of intravenous iron have demonstrated efficacy in raising hemoglobin, the quantity of administered intravenous iron has raised concerns about iron overload leading to long-term toxicities. The goal of this review is to understand recent trends in intravenous iron use, potential mechanisms of iron toxicity, and to evaluate the availabl...
Source: Advances in Chronic Kidney Disease - August 31, 2019 Category: Urology & Nephrology Source Type: research
Hepcidin
Publication date: July 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 4Author(s): Anil K. Agarwal, Jerry YeeDysregulation of metabolism and utilization of iron can lead to the development and maintenance of anemia of CKD. Anemia is prevalent among patients with CKD. The markers of iron sufficiency or availability of iron are far from perfect which results in inaccurate diagnosis and treatment of anemia with poor outcomes. Hepcidin, a 25 amino acid peptide produced by the hepatocytes, has emerged as the key regulator of uptake and release of iron in the tissues to maintain a steady supply of iron to erythr...
Source: Advances in Chronic Kidney Disease - August 31, 2019 Category: Urology & Nephrology Source Type: research
Masthead
Publication date: May 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 3Author(s): (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - June 13, 2019 Category: Urology & Nephrology Source Type: research
Editorial Board
Publication date: May 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 3Author(s): (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - June 13, 2019 Category: Urology & Nephrology Source Type: research
Table of Contents
Publication date: May 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 3Author(s): (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - June 13, 2019 Category: Urology & Nephrology Source Type: research
Eradicating the Viral Triad in Hemodialysis Units
Publication date: May 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 3Author(s): Beth Adams, Jerry Yee (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - June 13, 2019 Category: Urology & Nephrology Source Type: research
Warning: Kidney Virus Detected
Publication date: May 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 3Author(s): James E. Novak (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - June 13, 2019 Category: Urology & Nephrology Source Type: research
Common Mechanisms of Viral Injury to the Kidney
Publication date: May 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 3Author(s): Leslie A. BruggemanViral infections in an immunocompetent host can cause both acute and chronic kidney diseases, either by direct damage to the infected kidney cells or as a consequence of systemic immune responses that impact the kidneys' function. Viruses have evolved mechanisms to hijack signaling pathways of the infected cell, including the mammalian target of rapamycin pathway to support viral replication, and to evade antiviral immune responses such as those mediated by miR-155 via microRNA mimetics expressed by the vir...
Source: Advances in Chronic Kidney Disease - June 13, 2019 Category: Urology & Nephrology Source Type: research
Emerging Threat: Changing Epidemiology of Hepatitis A and Acute Kidney Injury
Publication date: May 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 3Author(s): Maria Andrievskaya, Adrienne Lenhart, Junior UdumanIn the past decade, hepatitis A has been considered a rare disease in the United States, largely due to targeted vaccination of at-risk children. Evolving epidemiology has resulted in decreasing immunity and increasing hepatitis A infections among adults who are more likely to experience severe disease. A surge in outbreaks has been noted in the past 2 years, resulting in a high volume of hepatitis A related hospitalizations and complications in otherwise healthy individuals...
Source: Advances in Chronic Kidney Disease - June 13, 2019 Category: Urology & Nephrology Source Type: research
